Bank of New York Mellon Corp Buys New Stake in Mesa Laboratories, Inc. $MLAB

Bank of New York Mellon Corp bought a new position in shares of Mesa Laboratories, Inc. (NASDAQ:MLAB - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 45,602 shares of the medical instruments supplier's stock, valued at approximately $4,540,000. Bank of New York Mellon Corp owned about 0.81% of Mesa Laboratories at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of MLAB. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Mesa Laboratories by 4.9% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 3,068 shares of the medical instruments supplier's stock valued at $364,000 after purchasing an additional 143 shares during the last quarter. American Century Companies Inc. lifted its position in shares of Mesa Laboratories by 1.5% during the 2nd quarter. American Century Companies Inc. now owns 13,431 shares of the medical instruments supplier's stock worth $1,265,000 after purchasing an additional 194 shares during the last quarter. BNP Paribas Financial Markets boosted its stake in Mesa Laboratories by 30.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,029 shares of the medical instruments supplier's stock valued at $69,000 after purchasing an additional 243 shares during the period. Deutsche Bank AG increased its position in Mesa Laboratories by 5.9% in the 4th quarter. Deutsche Bank AG now owns 4,440 shares of the medical instruments supplier's stock worth $349,000 after buying an additional 248 shares during the period. Finally, Northwestern Mutual Wealth Management Co. increased its position in Mesa Laboratories by 5,366.7% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 328 shares of the medical instruments supplier's stock worth $26,000 after buying an additional 322 shares during the period. 90.60% of the stock is currently owned by institutional investors.

Mesa Laboratories Trading Down 0.6%

MLAB stock opened at $127.78 on Friday. Mesa Laboratories, Inc. has a 1-year low of $58.83 and a 1-year high of $132.70. The company has a current ratio of 1.79, a quick ratio of 1.32 and a debt-to-equity ratio of 0.73. The business's 50 day moving average is $107.63 and its 200-day moving average is $99.88. The firm has a market cap of $715.57 million, a P/E ratio of 152.12 and a beta of 0.97.

Mesa Laboratories (NASDAQ:MLAB - Get Free Report) last announced its quarterly earnings results on Monday, August 10th. The medical instruments supplier reported $2.68 earnings per share for the quarter. The firm had revenue of $60.14 million for the quarter. Mesa Laboratories had a return on equity of 22.72% and a net margin of 1.92%.

Mesa Laboratories Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 15th. Investors of record on Monday, August 31st will be issued a dividend of $0.16 per share. This represents a $0.64 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date of this dividend is Monday, August 31st. Mesa Laboratories's dividend payout ratio (DPR) is currently 76.19%.

Insider Transactions at Mesa Laboratories

In related news, SVP Brian Archbold sold 2,516 shares of Mesa Laboratories stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $89.50, for a total value of $225,182.00. Following the completion of the transaction, the senior vice president directly owned 6,377 shares of the company's stock, valued at $570,741.50. The trade was a 28.29% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO John Sakys sold 2,827 shares of the company's stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $89.50, for a total transaction of $253,016.50. Following the transaction, the chief financial officer owned 19,785 shares in the company, valued at $1,770,757.50. The trade was a 12.50% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders have sold 15,370 shares of company stock worth $1,570,213. 2.80% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on MLAB. Weiss Ratings upgraded shares of Mesa Laboratories from a "sell (d)" rating to a "hold (c-)" rating in a research note on Tuesday, August 11th. Wells Fargo & Company upped their target price on shares of Mesa Laboratories from $94.00 to $110.00 and gave the company an "equal weight" rating in a research note on Friday, August 14th. Finally, Wall Street Zen downgraded shares of Mesa Laboratories from a "strong-buy" rating to a "buy" rating in a report on Saturday, August 15th. Three equities research analysts have rated the stock with a Hold rating, According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $110.00.

About Mesa Laboratories

Mesa Laboratories, Inc NASDAQ: MLAB is a global provider of instrumentation products designed for critical process monitoring, testing and calibration. Headquartered in Lakewood, Colorado, the company serves a diverse set of end markets including healthcare, pharmaceutical, food and beverage, energy and industrial sectors. With a focus on precision measurement and validation, Mesa Laboratories helps customers ensure regulatory compliance, product safety and operational efficiency across complex manufacturing and sterilization processes.

The company's product portfolio encompasses biological and chemical indicators for sterilization process validation, digital data loggers and sensors for environmental monitoring, and optical gas analyzers with sample-conditioning solutions for oil, gas and petrochemical applications.

Want to see what other hedge funds are holding MLAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mesa Laboratories, Inc. (NASDAQ:MLAB - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source